

Prescribing and Formulary Panel Minutes

Tuesday OCTOBER 11th 2022 5pm

Oak MDT Room

Present

Geraldine O’Riordan, Prescribing Advisor and Chair
Paul Williams, Island Health Medical Practice
Douglas Wilson, Queens Road Medical Practice
Mike McCarthy, Healthcare Group
Peter Gomes, Medical Specialist Group
Tom Saunders, Medical Specialist Group
Lucinda Cartwright, Community Dietician HSC (for enteral feed item)

Apologies

Andrew Ward,
Nikki Brink

Draft minutes

Draft minutes of the September 2022 meeting were approved

- **New Drugs**

IV ibuprofen had been requested by an Emergency Department Consultant as an NSAID with potentially fewer adverse effects on the renal system than the current first line agent, ketorolac, and as an alternative to opioids, but at a significantly higher cost. After a discussion about renal adverse effects and alternative products e.g. IV paracetamol, it was agreed that there was insufficient evidence to support its use at the present time.

Action: GOR

- **Minor and/or cost-neutral additions or changes to the Prescribing List or the Hospital Formulary**

The following were approved

- a. Removal of the restriction of dispensing of antacid and oxethacaine suspension to PEH only, as it is now available at a fixed reasonable price via retail pharmacies.
- b. Addition of Suprasorb P (non-border) dressing, all sizes, better value than Alleevyn or Mepilex Lite.

- **New NICE TAs** : none this month
- **Enteral feeds in care homes**

LC presented draft guidelines on the above, highlighting their relatively high use in homes and the difficulties surrounding stock availability for other patients entirely dependent on these products for nutrition. All strongly supported the “food first” approach and noted that wastage of these in care homes appeared to be high. The guideline recommended that for all care home patients, a dietetic referral was required before any prescribing could begin. The guidelines were approved unanimously.

Action : LC, GOR and All

- **Prescribing Support Unit Annual Report 2021**

GOR expressed appreciation to colleagues in Primary and Secondary Care for their hard work in delivering the pharmaceutical service in 2021.

- **Short burst oxygen therapy in cluster headache:**

V2 draft guidelines had been referred to Dr Basil Ridah for clarification on a small number of points.

Action : GOR

- **MCAs for new patients in their own homes in the community** draft policy and draft new request form were approved in the light of greatly reduced community pharmacy capacity. It was queried why nursing homes, who employ registered nurses, require medication in dosette boxes at extra expense.
- **Denosumab Guidelines** : for update attached and approved
- **Black Triangle Drugs** : attached and noted
- **DOAC Prescribing** : no change to DT cost of apixaban was reported, but several generics are listed in the on-line BNF. For some, the list price is higher than the cost of branded apixaban. They are possibly available to hospitals or to ICBs at lower prices via rebates. GOR is speaking to companies re a possible rebate. The annual cost of apixaban is approximately £324K.
- **New NMPs** : none
- **AOB**
- **Date of next meeting** Tuesday November 15th Oak MDT Room 5pm